Ignite Creation Date:
2024-05-06 @ 9:10 AM
Last Modification Date:
2024-10-26 @ 12:10 PM
Study NCT ID:
NCT02913118
Status:
UNKNOWN
Last Update Posted:
2018-04-10
First Post:
2016-09-12
Brief Title:
Adjunctive Therapy of Andrographolid Sulfonatein Community Acquired Pneumonia
Sponsor:
Qingfeng Pharmaceutical Group
Organization:
Qingfeng Pharmaceutical Group
Study Overview
Official Title:
Adjunctive Therapy of Andrographolid Sulfonatein Community Acquired Pneumonia A Multicenter Randomized Controlled Clinical Trial
Status:
UNKNOWN
Status Verified Date:
2018-04
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Adjunctive Therapy of AndrographolidSulfonate in Community Acquired Pneumonia A Multicenter RandomizedDouble-blinded Placebo Controlled Clinical Trial The hypothesis is that combination therapy with Andrographolid Sulfonatein injection and antibacterial is significantly better than antibacterial alone in achieving clinical stability among hospitalized CAP patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None